Rocket Pharmaceuticals announces $180M sale of priority review voucher

Rocket Pharmaceuticals (RCKT) announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher, PRV. Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded following the U.S. Food and Drug Administration, FDA, accelerated approval of Kresaldi. The transaction reflects the continued strategic value of PRVs, as well as Rocket’s disciplined approach to capital formation and allocation in support of its prioritized cardiovascular gene therapy programs. “The monetization of our PRV, following the FDA approval of Kresaldi, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of 2028,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. “This strengthens our ability to advance key clinical milestones across our cardiovascular gene therapy pipeline, with all programs on track.”